[Objective]To evaluate the clinical outcomes of unilateral biportal endoscopic transforaminal lumbar interbody fusion(UBE-TLIF)for recurrent lumbar disc herniation(RLDH).[Methods]A retrospective study was conducted on 38 patients who had RLDH treated surgically in our hospitals from January 2022 to December 2023.Based on preoperative doctor-patient communication,18 patients underwent UBE-TLIF,while other 20 patients received posterior lumbar interbody fusion(PLIF).Clinical and imaging data were evaluated and compared between the two groups.[Results]All patients in both groups were operated on successfully without neurological injury and other complications.The UBE-TLIF group proved significantly superior to the PLIF group in terms of operative time[(138.3±15.4)min vs(154.8±14.6)min,P=0.002],intraoperative blood loss[(186.1±41.0)ml vs(230.5±55.8)ml,P=0.009],the ambulation time[(2.4±0.6)days vs(5.9±1.0)days,P＜0.001],hospital stay[(8.1±2.3)days vs(12.4±2.9)days,P＜0.001].All patients in both groups were followed up for a mean of(5.42±1.10)months.The UBE-TLIF group proved significantly better than the PLIF group regarding to back pain VAS score[(2.2±0.7)vs(3.1±0.8),P=0.002],ODI score[(36.7±3.4)vs(57.0±3.9),P＜0.001]and JOA scores[(11.2±2.4)vs(9.2±2.5),P=0.018]1 day after surgery,whereas which became not statistically significant between the two groups at the latest follow-up(P＞0.05).[Conclusion]The UBE-TLIF achieves better early functional recovery,with the advantages of shorter operation time,less intraoperative blood loss,earlier ambulation time and shorter hospital stay over the PLIF.
NETL
NSTL
万方数据
